Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Oncology market is Big. 66% of BMY revenue

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 07, 2021 12:37pm

161 Views

Post# 33668402

RE:RE:Oncology market is Big. 66% of BMY revenue

The MUK eleven trial in multiple myeloma was terminated by BMS once it acquired Celgene, so ONCY pivoted to carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®) which demonstrated a clinical and anti-tumor inflammatory response induced with pelareorep-carfilzomib treatment in this extremely difficult to treat patient population with an 50% overall response rate and 83% Clinical Benefit Rate in patients who failed carfilzomib.

There is much you don't know about this stock Mr.Un-Notable

<< Previous

Bullboard Posts

Next >>

Online behaviour puts Canadians at risk of cyberattacks, study finds